Biogen buys a brain disorder drug for $217 million, but needs to go bigger, analyst says
January 25, 2018 at 12:44 PM EST
Massachusetts-based Biogen reported fourth-quarter revenue of $3.31 billion, above the $3.1 billion expected from analysts polled by Thomson Reuters.